For instance, what are the relative contributions in targeting tumors with AGF94 via FRα and PCFT versus FRβ-expressing TAMs to the net anti-tumor response observed, and are the CD3+ T-cells functional after treatment? The gene discussed is FOLR2; the disease is neoplasm.